name: | DoxazosinAndFinasteride | |
ATC code: | G04CA55 | route: | oral |
compartments: | 1 | |
dosage: | 5 | mg |
volume of distribution: | 40 | L |
clearance: | 1.5 | L/h |
other parameters in model implementation |
Doxazosin and finasteride is a combination drug used primarily in the treatment of benign prostatic hyperplasia (BPH) in men. Doxazosin is an alpha-1 adrenergic blocker that relaxes smooth muscle in the prostate and bladder neck, while finasteride is a 5-alpha-reductase inhibitor that lowers levels of dihydrotestosterone, resulting in shrinkage of the enlarged prostate. The fixed-dose combination is marketed in some regions but may not be universally approved or widely used.
No published population pharmacokinetic models for the fixed-dose combination of doxazosin and finasteride were identified. The following are estimates based on known pharmacokinetics of individual drugs in healthy adult males, assuming standard oral administration.